Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study by Christopher Ma, Candace L. Beilman, Vivian W. Huang, Darryl K. Fedorak, Karen Wong, Karen I. Kroeker, Levinus A. Dieleman, Brendan P. Halloran, Richard N. Fedorak

“…We aim to determine if earlier treatment with infliximab or adalimumab alters clinical and surgical outcomes in UC patients. …”
Get full text

Biologics in ocular inflammatory diseases – Experience from a tertiary referral eye care center in South India by Kalpana Babu, PG Padmapriya, Anand P Rao, Ramesh Jois

“…Adalimumab and rituximab were biosimilars, while tofacitinib was the generic version. …”
Get full text

Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers by Andrea Rodríguez-Lopez, María Martínez-Sendino, Rocío Prieto-Pérez, Paula Soria-Chacartegui, Eva González-Iglesias, Mario Aparicio-Domínguez, Sonsoles Berenguer-Ruiz, Esteban Daudén, Francisco Abad-Santos

“…This study aimed to evaluate the 10-year persistence of biologic drugs (adalimumab, etanercept, infliximab and ustekinumab) in the treatment of moderate-to-severe plaque psoriasis. …”
Get full text

Cytokines in Thyroid-Associated Ophthalmopathy by Pengbo Zhang, Huang Zhu

“…In recent years, cytokines and the immune responses they mediate have been crucial in disease progression, and currently, common evidence has shown that drugs targeting cytokines, such as tocilizumab, infliximab, and adalimumab, may be novel targets for therapy. In this review, we summarize the research development of different cytokines in TAO pathogenesis in the hope of discovering new therapeutic targets.…”
Get full text

Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study by Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang, Debra F. Eisenberg, David J. Harrison

“…**Objectives:** To implement a validated claims-based effectiveness algorithm in a US managed care claims database to compute the 1-year biologic cost per effectively treated patient among first-line biologics approved for moderate-to-severe RA (abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab). …”
Get full text

Genital and Intertriginous Rashes Refractory to Antimicrobial Treatments: Have You Thought about Crohn’s Disease? by Candelaria O’Farrell, Annette Roberts, Claudia Riera Canales, Carrie Firestone Baum, Lina Maria Felipez

“…The genital lesions resolved after starting treatment for Crohn’s disease with adalimumab.…”
Get full text

Is Exploration of Alternate Immune Pathways Needed in Hidradenitis Suppurativa? A Case of Atopic Dermatitis and Concurrent Hidradenitis Suppurativa Responding to Dupilumab by Sean McCormack, Noor Tazudeen, Benjamin C. Garden

“…Only one such biologic, adalimumab, has been approved by the US Food and Drug Administration (FDA) for the treatment of HS. …”
Get full text

Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy by Abhishek Bhat, Bruno Nahar, Vivek Venkatramani, Indraneel Banerjee, Oleksandr N. Kryvenko, Dipen J. Parekh

“…We describe a case of a right-sided metastatic RCC with Level IV thrombus initially managed with Pazopanib followed by Nivolumab and Adalimumab followed by cytoreductive nephrectomy and IVC thrombectomy in the post-targeted therapy setting with complete curative response.…”
Get full text

Rheumatoid Meningoencephalitis: A Feared Condition in the Era of TNF Blockers by Fernando Figueroa Rodriguez, Kwon Minkyung, Sruthi Jinna, Sohail Farshad, Francisco Davila

“…We present a case of rheumatoid meningoencephalitis (RME) in a 52-year-old male with a history of RA on adalimumab who presented with headaches associated with motor and sensory deficits, all of which resolved after this diagnosis was achieved and received appropriate therapy with high-dose glucocorticoids. …”
Get full text

Biologics in Paediatric Crohn's Disease by Oliver Gouldthorpe, Anthony G. Catto-Smith, George Alex

“…More information is needed about very long term risks. Infliximab and adalimumab are the most studied agents in children, while there is relatively limited data on certolizumab and natalizumab. …”
Get full text

Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury by Zhu Y, Xu G

“…Corresponding targeted medications such as Abatacept, chemokine receptor (CCR) inhibitors, CDDO-Im (2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide), adenosine monophosphate-activated protein kinase (AMPK) activators, and Adalimumab are currently under investigation. Notably, some medications such as Rituximab and Sparsentan, may simultaneously target multiple downstream mechanisms, Furthermore, exploring molecular strategies for established medications and developing novel treatments guided by biomarkers such as Anti-CD40 antibody, blood microRNA, urinary microRNA, and tumor necrosis factor-alpha (TNF-α) may provide additional therapeutic avenues for patients with FSGS.Keywords: focal segmental glomerulosclerosis, podocyte injury, targeted therapies, biomarkers…”
Get full text

Sarcoid of the Upper Humerus Found Incidentally on MR Images Obtained for Work-Up of Rotator Cuff Tear Where Compromised Tissue Quality Was a Concern for Surgical Success by Tanner R. Henrie, John G. Skedros

“…An excellent result was ultimately achieved after her rheumatologist started adalimumab injections. This case demonstrates that there can be a rare incidental finding of osseous sarcoid lesions in the upper humerus where the bone might be compromised in the location of a planned rotator cuff repair.…”
Get full text

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis by Cynthia Said, Bernard Coleiro, Maurice Zarb Adami, Lilian M. Azzopardi, Anthony Serracino Inglott

“…Due to the high costs associated with acquisition of this treatment, this study was undertaken to evaluate the ICER of TNF-α antagonists (etanercept, adalimumab, and infliximab) in improving the quality of life. …”
Get full text

Management of the Pregnant Inflammatory Bowel Disease Patient on Antitumour Necrosis Factor Therapy: State of the Art and Future Directions by Yvette PY Leung, Remo Panaccione, Subrata Ghosh, Cynthia H Seow

“…The World Congress of Gastroenterology consensus statement on biological therapy for IBD considered infliximab and adalimumab to be low risk and compatible with use during conception and during pregnancy in at least the first two trimesters. …”
Get full text

Rapidly Destructive Inflammatory Arthritis of the Hip by Jenny Shu, Ian Ross, Bret Wehrli, Richard W. McCalden, Lillian Barra

“…She required a right total hip arthroplasty, but arthritis in other joints showed improvement with triple disease modifying antirheumatic drugs (DMARD) therapy and almost complete remission with the addition of adalimumab. We contrast our case of RDC as an initial presentation of RA to 8 RDC case reports of patients with established RA. …”
Get full text

Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation by Chao-Yang Lai, Yu-Wen Su, Kuo-I Lin, Li-Chung Hsu, Tsung-Hsien Chuang

“…The currently approved biological drugs adalimumab, etanercept, infliximab, ustekinumab, ixekizumab, and secukizumab are antibodies against effector cytokines that participate in the initiation and development of psoriasis. …”
Get full text

Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn’s Disease by Sue Perera, Shibing Yang, Marni Stott-Miller, Joanne Brady

“…Of 1-year follow-up cohort patients, 45% received the same biologic initiated at index for ≥1 year. Infliximab and adalimumab were the most commonly initiated biologics in patients with UC or CD. …”
Get full text

Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study by Ece Erbağcı, Özge Sevil Karstarlı Bakay, Fatma Aslı Hapa

“…Nine (29%) patients were biologic-naive and 10 (32.3%) were adalimumab-naive. Disease severity was Hurley I in 7 patients (22.6%), Hurley II in 9 patients (29%), and Hurley III in 15 patients (48.4%). …”
Get full text

Management of Anal Fistula with Crohn's Disease by Shota Takano, Yasushi Nakamura, Kohei Tamaoka, Takafumi Yoshimoto, Yasue Irei, Yoriyuki Tsuji

“…PFCD management has greatly improved with the use of biologics such as the antitumor necrosis factor alpha (TNF-α) antibodies infliximab and adalimumab. In this review, the results of the administration of anti-TNF-α (certolizumab pegol), anti-interleukin-12/23 (ustekinumab), and anti-α4β7 integrin antibodies (vedolizumab) were evaluated. …”
Get full text

Surgical treatment of the fistulizing Crohn's disease with anterior abdominal wall reconstruction (Clinical case) by Yu. Ye. Kitsenko, O. S. Shifrin, P. V. Tsarkov

“…At continuation of biological therapy by adalimumab no data on disease relapse were received. …”
Get full text